EGFR is clinically validated as a therapeutic target with several FDA-approved ... in patients with EGFR-expressing tumors. The ALX2004 molecule, created entirely in ALX Oncology labs, comprises an ...

EGFR is one of the biomarkers of the basal-like subtype of breast carcinomas and might play a relevant role in its biological behavior, being a potential therapeutic target to this aggressive ...

Another reason for choosing a particular modality is that it is a team’s specialty. Strategic choices can be less about determining which modality best fits a potential target than about choosing a ...

Bicara Therapeutics shows potential to reshape cancer care with ficerafusp alfa and robust funding post-IPO. Find out why ...

an anti-EGFR IgA antibody that will now be developed under Epsilogen as EPS-401. The therapy is expected to enter the clinic next year. The broader pipeline includes additional IgE candidates ...

Gut Microbiota in Immuno-Oncology: A Practical Guide for Medical Oncologists With a Focus on Antibiotics Stewardship Bispecific antibodies ... targeting receptor tyrosine kinases such as amivantamab, ...

“Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic ...

“Our decision to license this Activin E-targeting functional antibody, a potentially first-in-class molecule, at this early stage reflects our firm belief in Activin E as a promising therapeutic ...

EGFR is clinically validated as a therapeutic target with several ... The ALX2004 molecule, created entirely in ALX Oncology labs, comprises an antibody backbone engineered to optimize anti ...